Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Abstract: A thrust reverser for a turbojet aircraft nacelle includes a fixed structure, a movable structure and an actuator. The actuator extends along a main axis and is connected by a first connection to the fixed structure and by a second connection to the movable structure for the deployment of the movable structure between a direct jet position and a reverse jet position. The actuator is also connected to the fixed structure by a third connection arranged longitudinally between the first connection and the second connection. An axis of the third connection is radially eccentric from the main axis and the third connection allows a predetermined displacement of the actuator with respect to the fixed structure.

Abstract: A thrust reverser with movable grids, includes structure for connecting, by recessing, a front frame of an outer cowl and a rear frame of the grids. The reverser includes loading structure configured to exert a stress pressing against the connecting structure, under the action of a circumferential pull of the front frame of the outer cowl or of a tightening band supported by the front frame.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: A nacelle for a propulsion assembly, the nacelle including a front internal structure having a framework formed of longitudinal beams and including removable, dismountable or retractable panels which are provided to facilitate the access for maintenance to the parts of the motor shrouded by these panels.

Abstract: In certain aspects, the present disclosure relates to methods of treating Hermansky-Pudlak Syndrome (HPS) using a T?RII antagonist. In part, the disclosure provides T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with HPS, including complications associated with fibrosis and/or the lung (e.g., pulmonary fibrosis, interstitial lung disease (ILD)).

Abstract: In certain aspects, the present disclosure relates to methods of treating chronic liver disease, portal hypertension, primary sclerosing cholangitis, and hepatopulmonary syndrome, particularly associated clinical complications such as, for example, pulmonary fibrosis and/or interstitial lung disease (ILD), methods comprising administering T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with chronic liver disease, including interstitial lung disease (ILD) and pulmonary fibrosis, with T?RII antagonists of the present disclosure.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.

Abstract: A thrust reverser for a propulsion unit, incudes movable grids, two half-assemblies forming part of a secondary stream and, at the six o'clock position, a connecting beam intended to be mounted in cantilever with a fan housing. The half-assemblies are hinged at the twelve o'clock position so as to enable their “butterfly” movement between a flight configuration and a maintenance configuration. The connecting beam includes a connecting member configured to cooperate, in the form of a tenon and groove connection, with the half-assemblies when these are in flight configuration. The reverser also includes, downstreamof the connecting member, locks capable of locking the half-assemblies in flight configuration.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Abstract: A nacelle for a propulsion assembly, the nacelle including a front internal structure having a framework formed of longitudinal beams and including removable, dismountable or retractable panels which are provided to facilitate the access for maintenance to the parts of the motor shrouded by these panels.

Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: The present invention relates to the field of solid materials for the adsorption of lithium. In particular, the present invention relates to a new method for the preparation of a crystallized and shaped solid material, preferably in extruded form, of the formula (LiCl)x.2Al(OH)3,nH2O, wherein n is between 0.01 and 10, x is between 0.4 and 1, wherein it comprises a step a) of precipitation of boehmite under specific temperature and pH conditions, a step of bringing into contact the precipitate obtained with LiCl, at least one acid extrusion-kneading shaping step, wherein the method also comprises a final hydrothermal treatment step, all of which makes it possible to increase the lithium adsorption capacity, the adsorption kinetics, as well as the lithium/boron selectivity of the materials obtained with respect to the materials of the prior art, when it is used in a lithium extraction method of saline solutions.

Abstract: A thrust reverser for a turbojet aircraft nacelle includes a fixed structure, a movable structure and an actuator. The actuator extends along a main axis and is connected by a first connection to the fixed structure and by a second connection to the movable structure for the deployment of the movable structure between a direct jet position and a reverse jet position. The actuator is also connected to the fixed structure by a third connection arranged longitudinally between the first connection and the second connection. An axis of the third connection is radially eccentric from the main axis and the third connection allows a predetermined displacement of the actuator with respect to the fixed structure.

Abstract: Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.